Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol

Clinical and Experimental Nephrology

Volumn 8, Issue 2, 2004, Pages 134-138

  Murakami, Kazutaka ^a   Miyachi, Hiromi ^a   Watanabe, Asako ^a   Kawamura, Nahoko ^a   Fujii, Mikiko ^a   Koide, Shigehisa ^a   Murase, Masamitsu ^a   Kushimoto, Hiroko ^a   Hasegawa, Midori ^a   Tomita, Makoto ^a   Hiki, Yoshiyuki ^a   Sugiyama, Satoshi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CAPD; Intraperitoneal administration; Maxacalcitol; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; CALCIUM ION; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG BLOOD LEVEL; DRUG PERITONEAL FLUID LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM;

EID: 3142554184     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-004-0283-1     Document Type: Article

References (9)

1. 3 analogues. Chem Pharm Bull 1986;34:4410-13.
2. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K. Clinical effects of Maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38:147-51.
3. 3. J Nutr Sci Vitaminol (Tokyo) 1989;35:529-33.
4. Kobayashi T, Okano T, Tsugawa N, Masuda S, Takeuchi A, Nishii Y. Metabolism and transporting system of 22-oxacalcitriol. Contrib Nephrol 1991;91:129-33.
5. Arora N, Sandroni S, Moles K. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol. Peritoneal Dial Bull 1992;8:62-4.
6. Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N, et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 1987;31:795-9.
7. Chan HWH, Tsang W-K, Chan C-M, Fung SKS, So S-O, Tang H-L, et al. Intraperitoneal pulse calcitriol in treatment of secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1998:18:177-82.
8. Salusky I, Goodman W, Horst R, Segre G, Kim L, Norris K. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 1990;16:126-32.
9. Tsunoo M, Shishido R, Ogata E. Clinical I-phase test by one-time and intermittent intravenous injection of a new derivative of 1 alpha, 25-dihydroxyvitamin D3, 22-oxacalcitriol (OCT) (in Japanese). Jpn J Clin Dialysis 1999;15:137-61.